Skip to main content

Table 2 Patient characteristics of incident GnRH agonist users

From: Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

Incident GnRH agonist users

Characteristics

Strata

SEER groupa

Non-SEER groupb

Proportion not in SEER group

 
  

n

nc

%

p-valued

Total

 

17424

1700

8.9

 

Year of diagnosis

1993

2008

190

8.6

0.26

 

1994

1983

269

11.9

 
 

1995

2034

178

8.0

 
 

1996

2330

265

10.2

 
 

1997

2750

215

7.3

 
 

1998

2964

260

8.1

 
 

1999

3355

323

8.8

 

Age at diagnosis (years)

67 – 74

8209

653

7.4

0.11

 

≥75

9215

1047

10.2

 

Race

White

14484

1395

8.8

0.70

 

Black

1626

199

10.9

 
 

Other/Unknown

1314

106

7.5

 

Region

Northeast

2570

265

9.3

0.15

 

Midwest

5597

351

5.9

 
 

South

1331

156

10.5

 
 

West

7926

928

10.5

 

Zip education

< 12.5%

4223

294

6.5

0.65

(% adult <12 years education)

≥12.5%

12090

966

7.4

 

Comorbidity Index

0

12604

1045

7.7

0.03

 

≥1

4820

655

12.0

 
  1. aDiagnosis of prostate cancer registered in SEER
  2. bDiagnosis of prostate cancer from Medicare claims, but not in SEER, and excluding men who may have had a delay in reporting, moved out of the SEER area at the time of diagnosis or failed the SEER to Medicare linkage
  3. cSample size inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
  4. dChi-square test for comparison of proportions across strata for each characteristic, based on uninflated sample sizes. P-value reported for year of diagnosis is based on test for linear trend
  5. GnRH; Gonadotropin-releasing hormone
  6. SEER; Surveillance, Epidemiology and End-Results